Position
Creative Planning in Corvus Pharmaceuticals, Inc.
Back to the book · All holders of CRVS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $271.5K$7.70 → $14.63
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 39.2K | $301.7K | — | — | — | 0.0% |
| Q1 2026 | 43K | $629.6K | $14.63 | $271.5K | $56.4K | 0.0% |